| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 55 | 2022 | 483 | 5.400 |
Why?
|
| Genome-Wide Association Study | 46 | 2023 | 1671 | 3.200 |
Why?
|
| Homosexuality, Male | 7 | 2021 | 299 | 2.250 |
Why?
|
| Polymorphism, Single Nucleotide | 41 | 2023 | 2401 | 1.630 |
Why?
|
| Heterosexuality | 4 | 2021 | 18 | 1.620 |
Why?
|
| Gender Identity | 2 | 2021 | 53 | 1.440 |
Why?
|
| Genetic Predisposition to Disease | 37 | 2024 | 2340 | 1.320 |
Why?
|
| Genetic Linkage | 18 | 2021 | 624 | 1.310 |
Why?
|
| Mental Disorders | 10 | 2024 | 414 | 1.160 |
Why?
|
| Induced Pluripotent Stem Cells | 6 | 2024 | 117 | 1.010 |
Why?
|
| Depressive Disorder, Major | 8 | 2023 | 166 | 0.990 |
Why?
|
| Genome, Human | 12 | 2021 | 767 | 0.860 |
Why?
|
| Bipolar Disorder | 15 | 2021 | 387 | 0.770 |
Why?
|
| Genetic Variation | 12 | 2018 | 1374 | 0.740 |
Why?
|
| DNA Copy Number Variations | 10 | 2022 | 177 | 0.610 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2014 | 85 | 0.610 |
Why?
|
| Alleles | 15 | 2024 | 1135 | 0.590 |
Why?
|
| Sequence Analysis, RNA | 3 | 2018 | 233 | 0.580 |
Why?
|
| Humans | 100 | 2024 | 89349 | 0.560 |
Why?
|
| Genotype | 22 | 2019 | 1849 | 0.560 |
Why?
|
| General Practitioners | 1 | 2016 | 11 | 0.560 |
Why?
|
| Transcriptome | 4 | 2018 | 630 | 0.540 |
Why?
|
| Male | 51 | 2021 | 42410 | 0.540 |
Why?
|
| Chromosome Mapping | 19 | 2015 | 1076 | 0.530 |
Why?
|
| Gene Expression Regulation | 7 | 2018 | 1976 | 0.510 |
Why?
|
| Chromosomes, Human, X | 1 | 2014 | 55 | 0.480 |
Why?
|
| Patient Participation | 1 | 2016 | 224 | 0.470 |
Why?
|
| Family | 3 | 2009 | 325 | 0.470 |
Why?
|
| Sexual Behavior | 3 | 2021 | 311 | 0.470 |
Why?
|
| Referral and Consultation | 1 | 2016 | 341 | 0.450 |
Why?
|
| Communication | 1 | 2016 | 459 | 0.420 |
Why?
|
| Genetic Loci | 5 | 2023 | 253 | 0.420 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 1431 | 0.410 |
Why?
|
| Chromosomes, Human, Pair 6 | 6 | 2009 | 125 | 0.410 |
Why?
|
| Parity | 1 | 2012 | 96 | 0.400 |
Why?
|
| Receptors, Serotonin | 2 | 2002 | 34 | 0.400 |
Why?
|
| Female | 47 | 2021 | 46200 | 0.400 |
Why?
|
| Phenotype | 10 | 2021 | 2440 | 0.400 |
Why?
|
| Case-Control Studies | 13 | 2019 | 1862 | 0.400 |
Why?
|
| Fertility | 1 | 2012 | 117 | 0.390 |
Why?
|
| Chromatin | 3 | 2020 | 397 | 0.390 |
Why?
|
| Siblings | 3 | 2021 | 111 | 0.390 |
Why?
|
| Multifactorial Inheritance | 4 | 2019 | 169 | 0.380 |
Why?
|
| Linkage Disequilibrium | 13 | 2016 | 477 | 0.380 |
Why?
|
| Mothers | 1 | 2012 | 142 | 0.380 |
Why?
|
| Quantitative Trait Loci | 6 | 2020 | 608 | 0.370 |
Why?
|
| Haplotypes | 7 | 2008 | 637 | 0.370 |
Why?
|
| Decision Making | 1 | 2016 | 667 | 0.370 |
Why?
|
| Genetic Markers | 10 | 2016 | 478 | 0.350 |
Why?
|
| Psychotic Disorders | 4 | 2021 | 195 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 22 | 2 | 2005 | 44 | 0.310 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2008 | 69 | 0.310 |
Why?
|
| Adult | 23 | 2018 | 26607 | 0.300 |
Why?
|
| Internet | 1 | 2010 | 319 | 0.300 |
Why?
|
| Lod Score | 9 | 2021 | 152 | 0.290 |
Why?
|
| Genetics, Behavioral | 2 | 2004 | 22 | 0.280 |
Why?
|
| Body Height | 3 | 2013 | 100 | 0.280 |
Why?
|
| Pedigree | 15 | 2012 | 970 | 0.280 |
Why?
|
| Brain | 6 | 2020 | 2285 | 0.280 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2024 | 44 | 0.260 |
Why?
|
| Body Mass Index | 4 | 2015 | 773 | 0.260 |
Why?
|
| Sequence Deletion | 2 | 2019 | 205 | 0.260 |
Why?
|
| Suicide, Attempted | 3 | 2023 | 133 | 0.250 |
Why?
|
| Base Sequence | 9 | 2017 | 2327 | 0.240 |
Why?
|
| Gene Frequency | 10 | 2014 | 685 | 0.240 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 167 | 0.240 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 46 | 0.240 |
Why?
|
| Phosphoproteins | 1 | 2005 | 261 | 0.230 |
Why?
|
| Gene Regulatory Networks | 2 | 2018 | 308 | 0.220 |
Why?
|
| Middle Aged | 15 | 2018 | 25974 | 0.220 |
Why?
|
| Psychopharmacology | 1 | 2002 | 26 | 0.210 |
Why?
|
| Population Health | 1 | 2022 | 33 | 0.200 |
Why?
|
| Schizophrenic Psychology | 2 | 2012 | 133 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2017 | 51 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 18 | 6 | 1999 | 42 | 0.200 |
Why?
|
| Risk Factors | 9 | 2023 | 5498 | 0.200 |
Why?
|
| Nicotine | 2 | 2021 | 199 | 0.190 |
Why?
|
| Biological Evolution | 1 | 2009 | 965 | 0.190 |
Why?
|
| Sex Characteristics | 2 | 2021 | 326 | 0.190 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 115 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 15 | 3 | 2016 | 66 | 0.180 |
Why?
|
| Sexual Partners | 1 | 2021 | 101 | 0.180 |
Why?
|
| Adolescent | 10 | 2018 | 9263 | 0.180 |
Why?
|
| Choice Behavior | 1 | 2021 | 160 | 0.180 |
Why?
|
| Proteome | 1 | 2001 | 132 | 0.170 |
Why?
|
| Homosexuality, Female | 1 | 2019 | 15 | 0.170 |
Why?
|
| Neurons | 4 | 2022 | 1583 | 0.160 |
Why?
|
| Behavior, Addictive | 1 | 2021 | 134 | 0.160 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 3 | 2003 | 8 | 0.160 |
Why?
|
| Dopamine Antagonists | 1 | 2018 | 34 | 0.160 |
Why?
|
| Dopamine | 2 | 2018 | 276 | 0.150 |
Why?
|
| Smoking | 2 | 2012 | 621 | 0.150 |
Why?
|
| Sexual and Gender Minorities | 1 | 2021 | 208 | 0.150 |
Why?
|
| X Chromosome Inactivation | 1 | 2017 | 28 | 0.150 |
Why?
|
| Receptors, Thyrotropin | 1 | 2017 | 47 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2017 | 49 | 0.150 |
Why?
|
| DNA | 2 | 2002 | 1308 | 0.150 |
Why?
|
| Body Size | 2 | 2015 | 92 | 0.150 |
Why?
|
| Chromosomes, Human | 3 | 2009 | 66 | 0.150 |
Why?
|
| Neurogenesis | 1 | 2018 | 76 | 0.150 |
Why?
|
| Hippocampus | 1 | 2001 | 447 | 0.140 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1997 | 101 | 0.140 |
Why?
|
| Molecular Sequence Annotation | 2 | 2016 | 69 | 0.140 |
Why?
|
| Brain Diseases | 1 | 2018 | 186 | 0.140 |
Why?
|
| Informed Consent | 1 | 2019 | 275 | 0.140 |
Why?
|
| Nervous System | 1 | 2017 | 89 | 0.140 |
Why?
|
| Obesity | 3 | 2013 | 971 | 0.140 |
Why?
|
| Genome | 1 | 2019 | 386 | 0.140 |
Why?
|
| Paternal Inheritance | 1 | 2016 | 3 | 0.140 |
Why?
|
| Prader-Willi Syndrome | 1 | 2016 | 8 | 0.140 |
Why?
|
| Angelman Syndrome | 1 | 2016 | 7 | 0.140 |
Why?
|
| Cell Line | 3 | 2018 | 2496 | 0.140 |
Why?
|
| Models, Genetic | 3 | 2016 | 945 | 0.140 |
Why?
|
| Statistics as Topic | 1 | 2017 | 234 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 84 | 0.130 |
Why?
|
| Fetus | 2 | 2016 | 232 | 0.130 |
Why?
|
| Educational Status | 1 | 2016 | 194 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2012 | 492 | 0.120 |
Why?
|
| Autism Spectrum Disorder | 1 | 2016 | 82 | 0.120 |
Why?
|
| Molecular Sequence Data | 7 | 2014 | 3027 | 0.120 |
Why?
|
| Young Adult | 6 | 2018 | 6312 | 0.120 |
Why?
|
| United Kingdom | 3 | 2021 | 164 | 0.120 |
Why?
|
| Educational Measurement | 1 | 2016 | 231 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2013 | 79 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2017 | 1223 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2011 | 54 | 0.120 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2015 | 170 | 0.110 |
Why?
|
| Williams Syndrome | 1 | 2013 | 4 | 0.110 |
Why?
|
| Autistic Disorder | 2 | 2012 | 150 | 0.110 |
Why?
|
| MicroRNAs | 2 | 2017 | 551 | 0.110 |
Why?
|
| Hydroxymethylbilane Synthase | 1 | 1993 | 1 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2013 | 79 | 0.110 |
Why?
|
| Anthropometry | 1 | 2013 | 75 | 0.110 |
Why?
|
| United States | 6 | 2022 | 6987 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 4 | 2019 | 866 | 0.110 |
Why?
|
| Amino Acid Substitution | 2 | 2005 | 338 | 0.100 |
Why?
|
| Gene Expression | 5 | 2010 | 1310 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2022 | 2869 | 0.100 |
Why?
|
| Aged | 8 | 2018 | 19165 | 0.100 |
Why?
|
| Apoptosis | 1 | 2018 | 1717 | 0.100 |
Why?
|
| Europe | 5 | 2012 | 321 | 0.100 |
Why?
|
| Receptors, Nicotinic | 1 | 2012 | 131 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 511 | 0.100 |
Why?
|
| Tobacco Use Disorder | 1 | 2012 | 115 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 507 | 0.090 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 825 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2002 | 100 | 0.090 |
Why?
|
| Amino Acid Sequence | 4 | 2002 | 2062 | 0.090 |
Why?
|
| Risk | 3 | 2020 | 657 | 0.090 |
Why?
|
| Personality Assessment | 1 | 2010 | 97 | 0.090 |
Why?
|
| Self-Assessment | 1 | 2010 | 47 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2011 | 229 | 0.090 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2010 | 82 | 0.090 |
Why?
|
| Codon, Nonsense | 2 | 2024 | 44 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2011 | 216 | 0.090 |
Why?
|
| Birth Order | 1 | 2009 | 7 | 0.080 |
Why?
|
| Gene-Environment Interaction | 3 | 2016 | 112 | 0.080 |
Why?
|
| Alcoholism | 1 | 2011 | 178 | 0.080 |
Why?
|
| Body Weight | 1 | 2010 | 452 | 0.080 |
Why?
|
| Hair | 1 | 2009 | 56 | 0.080 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2008 | 12 | 0.080 |
Why?
|
| RNA | 1 | 2013 | 580 | 0.080 |
Why?
|
| Functional Laterality | 1 | 2009 | 200 | 0.080 |
Why?
|
| RNA Stability | 2 | 2013 | 89 | 0.080 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2008 | 100 | 0.080 |
Why?
|
| Quality Control | 1 | 2008 | 117 | 0.070 |
Why?
|
| Age of Onset | 4 | 2012 | 312 | 0.070 |
Why?
|
| Synapses | 2 | 2022 | 279 | 0.070 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2001 | 147 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 3041 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2003 | 2017 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 3 | 2013 | 85 | 0.070 |
Why?
|
| Prevalence | 1 | 2010 | 1243 | 0.070 |
Why?
|
| Genomics | 2 | 2022 | 762 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 106 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2008 | 3666 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 3 | 2017 | 956 | 0.060 |
Why?
|
| Thioredoxin Reductase 2 | 1 | 2005 | 2 | 0.060 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2005 | 4 | 0.060 |
Why?
|
| Armadillo Domain Proteins | 1 | 2005 | 3 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2001 | 855 | 0.060 |
Why?
|
| Cullin Proteins | 1 | 2024 | 8 | 0.060 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2024 | 8 | 0.060 |
Why?
|
| Pregnancy | 1 | 2012 | 3018 | 0.060 |
Why?
|
| Waist-Hip Ratio | 2 | 2015 | 20 | 0.060 |
Why?
|
| Gene Editing | 1 | 2024 | 48 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2024 | 202 | 0.060 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 78 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1714 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2007 | 681 | 0.060 |
Why?
|
| Receptors, Dopamine | 1 | 2003 | 37 | 0.050 |
Why?
|
| Nucleic Acid Conformation | 2 | 2003 | 342 | 0.050 |
Why?
|
| Suicidal Ideation | 1 | 2023 | 73 | 0.050 |
Why?
|
| Cloning, Molecular | 3 | 1998 | 646 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 3384 | 0.050 |
Why?
|
| Disease Susceptibility | 3 | 1998 | 200 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 50 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 401 | 0.050 |
Why?
|
| Sulfurtransferases | 1 | 2021 | 6 | 0.050 |
Why?
|
| Electrophoresis | 1 | 2001 | 55 | 0.050 |
Why?
|
| Rats, Inbred F344 | 1 | 2021 | 154 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2018 | 1525 | 0.050 |
Why?
|
| Computational Biology | 2 | 2016 | 543 | 0.050 |
Why?
|
| Mental Health | 1 | 2022 | 178 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2021 | 72 | 0.050 |
Why?
|
| Adoption | 2 | 2011 | 9 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2001 | 122 | 0.050 |
Why?
|
| Microsatellite Repeats | 4 | 2002 | 148 | 0.040 |
Why?
|
| Sp4 Transcription Factor | 2 | 2010 | 2 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 21 | 2 | 1997 | 54 | 0.040 |
Why?
|
| Logistic Models | 3 | 2011 | 1213 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 726 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 1997 | 392 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| Mutation | 2 | 2003 | 4143 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 6811 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2022 | 347 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2020 | 280 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 695 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2021 | 460 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 1998 | 55 | 0.040 |
Why?
|
| Calcium | 1 | 2022 | 1175 | 0.040 |
Why?
|
| DNA Footprinting | 1 | 2017 | 18 | 0.040 |
Why?
|
| RNA Editing | 1 | 1998 | 35 | 0.040 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2018 | 124 | 0.040 |
Why?
|
| Genes | 1 | 1998 | 305 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1997 | 51 | 0.040 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 2 | 1996 | 31 | 0.040 |
Why?
|
| Multigene Family | 1 | 1997 | 203 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1997 | 127 | 0.040 |
Why?
|
| Dendrites | 1 | 2017 | 102 | 0.030 |
Why?
|
| Gene Library | 1 | 1997 | 133 | 0.030 |
Why?
|
| Animals | 4 | 2021 | 27369 | 0.030 |
Why?
|
| Chromosome Duplication | 1 | 2016 | 8 | 0.030 |
Why?
|
| Receptors, Dopamine D2 | 1 | 1996 | 57 | 0.030 |
Why?
|
| Genomic Imprinting | 1 | 2016 | 33 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 773 | 0.030 |
Why?
|
| Neuregulin-1 | 2 | 2006 | 16 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2008 | 47 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2001 | 841 | 0.030 |
Why?
|
| Rats | 1 | 2021 | 4041 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 1996 | 922 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2623 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2014 | 275 | 0.030 |
Why?
|
| Nuclear Family | 3 | 2000 | 93 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 4289 | 0.030 |
Why?
|
| Sweden | 1 | 2013 | 40 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 1488 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2013 | 63 | 0.030 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 48 | 0.030 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2013 | 39 | 0.030 |
Why?
|
| Base Composition | 1 | 2013 | 35 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 1157 | 0.030 |
Why?
|
| HapMap Project | 1 | 2013 | 47 | 0.030 |
Why?
|
| Half-Life | 1 | 2013 | 97 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 1993 | 60 | 0.030 |
Why?
|
| Adolescent Development | 1 | 2012 | 21 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 114 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 1097 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 1652 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2016 | 499 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2013 | 188 | 0.020 |
Why?
|
| Cognition | 1 | 2016 | 580 | 0.020 |
Why?
|
| Genes, Recessive | 2 | 2002 | 87 | 0.020 |
Why?
|
| Twin Studies as Topic | 1 | 2011 | 19 | 0.020 |
Why?
|
| Genetic Pleiotropy | 1 | 2011 | 25 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1870 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 899 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 294 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 327 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 683 | 0.020 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2009 | 19 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
| Twins | 1 | 2010 | 65 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2012 | 269 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1072 | 0.020 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2009 | 51 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 160 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2000 | 306 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2017 | 1653 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2009 | 84 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2012 | 406 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 2558 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1877 | 0.020 |
Why?
|
| Environment | 1 | 2010 | 223 | 0.020 |
Why?
|
| Dysbindin | 1 | 2007 | 2 | 0.020 |
Why?
|
| Dystrophin-Associated Proteins | 1 | 2007 | 2 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1144 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2013 | 762 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 1066 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 1840 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2003 | 51 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2003 | 65 | 0.010 |
Why?
|
| CHO Cells | 1 | 2003 | 187 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2004 | 129 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2003 | 92 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2004 | 263 | 0.010 |
Why?
|
| Cricetinae | 1 | 2003 | 558 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 529 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 294 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 887 | 0.010 |
Why?
|
| Africa | 1 | 2002 | 101 | 0.010 |
Why?
|
| Australia | 1 | 2002 | 101 | 0.010 |
Why?
|
| Child | 1 | 2013 | 7173 | 0.010 |
Why?
|
| Canada | 1 | 2002 | 208 | 0.010 |
Why?
|
| Family Health | 1 | 2001 | 162 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 389 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2000 | 40 | 0.010 |
Why?
|
| Infant | 2 | 1998 | 3157 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2000 | 117 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2000 | 94 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2000 | 109 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 727 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 2362 | 0.010 |
Why?
|
| Sequence Tagged Sites | 1 | 1997 | 11 | 0.010 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 1997 | 37 | 0.010 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 1997 | 22 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 1997 | 32 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1997 | 71 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1997 | 48 | 0.010 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1997 | 7 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1997 | 59 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1997 | 86 | 0.010 |
Why?
|
| Receptors, Dopamine D3 | 1 | 1996 | 18 | 0.010 |
Why?
|
| Introns | 1 | 1998 | 299 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 1997 | 251 | 0.010 |
Why?
|
| Homozygote | 1 | 1996 | 204 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1998 | 211 | 0.010 |
Why?
|
| Exons | 1 | 1998 | 451 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1996 | 135 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 1998 | 740 | 0.010 |
Why?
|
| Models, Statistical | 1 | 1999 | 576 | 0.010 |
Why?
|
| Heterozygote | 1 | 1996 | 373 | 0.010 |
Why?
|
| Risk Assessment | 1 | 1996 | 2303 | 0.000 |
Why?
|